A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma

Trial Profile

A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Bendamustine (Primary) ; Cytarabine; Etoposide; Melphalan
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms BENEFIT
  • Most Recent Events

    • 03 Aug 2017 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2018.
    • 21 Nov 2016 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.
    • 21 Nov 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top